Hormone replacement therapy for menopause: understanding the new scientific recommendations
A recent update published by the Cochrane network on September 4, 2026, has reignited the debate surrounding hormone replacement therapy (HRT) for menopause. This international study confirms the existence of several health risks associated with the prolonged use of these hormonal treatments.
However, French health authorities emphasize that these findings cannot be applied directly to the situation in France. The French healthcare system uses specific protocols, with dosages and modes of administration that differ from those observed in international studies.
In France, HRT is prescribed on a personalized basis. Doctors adapt the treatment according to each patient's medical history and often favor lower doses administered transdermally, which helps to limit some of the side effects identified by the Cochrane study.
It is therefore advised that the women concerned do not modify or stop their treatment without consulting their general practitioner or gynecologist. These healthcare professionals are best placed to evaluate the benefit-risk ratio specific to each individual situation.
In conclusion, while this international study provides important scientific information, it does not call into question French medical practice. Dialogue with a specialist remains the essential step for any patient wishing to review their health during menopause.